JPMorgan Chase & Co. bought a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 6,380 shares of the company’s stock, valued at approximately $134,000.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in DYN. BlackRock Inc. increased its stake in shares of Dyne Therapeutics by 240.8% in the 4th quarter. BlackRock Inc. now owns 1,036,117 shares of the company’s stock valued at $21,757,000 after buying an additional 732,117 shares during the period. Caas Capital Management LP raised its holdings in Dyne Therapeutics by 1,590.1% during the fourth quarter. Caas Capital Management LP now owns 185,911 shares of the company’s stock worth $3,904,000 after acquiring an additional 174,911 shares in the last quarter. Northern Trust Corp bought a new stake in Dyne Therapeutics during the fourth quarter worth about $3,408,000. Charles Schwab Investment Management Inc. acquired a new position in Dyne Therapeutics during the fourth quarter worth approximately $1,728,000. Finally, Alyeska Investment Group L.P. increased its position in Dyne Therapeutics by 169.1% during the fourth quarter. Alyeska Investment Group L.P. now owns 78,566 shares of the company’s stock worth $1,650,000 after buying an additional 49,371 shares during the last quarter. 59.43% of the stock is currently owned by hedge funds and other institutional investors.
A number of equities research analysts recently issued reports on DYN shares. Zacks Investment Research raised Dyne Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday. Jonestrading initiated coverage on Dyne Therapeutics in a research note on Tuesday, February 9th. They issued a “buy” rating for the company. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $31.60.
Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Thursday, May 6th. The company reported ($0.50) EPS for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.10. Analysts anticipate that Dyne Therapeutics, Inc. will post -2.25 earnings per share for the current fiscal year.
Dyne Therapeutics Profile
Dyne Therapeutics, Inc, a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.
Recommended Story: Why are gap-down stocks important?
Want to see what other hedge funds are holding DYN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dyne Therapeutics, Inc. (NASDAQ:DYN).
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.